Investing

Ionis Pharmaceuticals : IONS

IONS

Stock Data

$56.56

$2.07 (3.80%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Ionis Pharmaceuticals Inc is a pioneer in creating RNA-targeted therapeutics. With a focus on serious and rare diseases, it has brought to market treatments like SPINRAZA for spinal muscular atrophy and TEGSEDI for polyneuropathy caused by hereditary transthyretin amyloidosis. The company is also advancing a robust pipeline of medicines targeting conditions such as amyotrophic lateral sclerosis, cardiovascular disease, and hepatitis B, among others. Ionis collaborates with leading pharmaceutical companies to enhance its reach and impact. Based in Carlsbad, California, Ionis continues to push the boundaries of medical science.

Latest Activity

IONSIonis Pharmaceuticals

Q2 2026

Jul 29, 7:31am ET

EPS

-$0.69

est -$0.88+21.4%

Revenue

$268M

est $190M+41.0%

Ionis beat revenue estimates by 41% on blockbuster new medicine launches and accelerating royalty income, while losses narrowed sharply despite the absence of a $280M one-time payment that juiced last year's quarter; DAWNZERA and TRYNGOLZA are ramping fast enough that management reaffirmed its path to cash-flow breakeven by 2028.

ShareRead more

All Ionis Pharmaceuticals Articles

8 Articles

Danielle Liverance | Jul 10, 2026 at 3:37 PM EDT

Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up

A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple…

David Moadel | May 19, 2026 at 12:15 PM EDT

Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk

BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance…

Joel South | Mar 26, 2026 at 11:27 AM EDT

Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) has delivered a remarkable 137.52% gain over the past year, though the stock…

Trey Thoelcke | Feb 5, 2025 at 8:45 AM EST

Prediction: This Pharma Stock Will Be the Best Performer in 2025

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big…

Chris Lange | Feb 1, 2022 at 8:53 AM EST

Tuesday’s Top Analyst Upgrades and Downgrades: ConocoPhillips, Livent, Luminar Technologies, Meta Platforms, Moderna, Snap, Twitter, United Airlines, Workday, Wells Fargo and More

Tuesday's top analyst upgrades and downgrades included BioNTech, ConocoPhillips, Harley-Davidson, Livent, Luminar Technologies, Meta Platforms, Moderna, Snap, Twitter, United Airlines,…

Chris Lange | May 7, 2021 at 12:10 PM EDT

Etsy, Monster Beverage, Nokia and More Friday Afternoon Analyst Calls

24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate…

Chris Lange | Aug 31, 2020 at 11:01 AM EDT

What Akcea Shareholders Get in the Ionis Buyout

Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding…

Chris Lange | Jan 22, 2020 at 10:30 AM EST

Why This Cardiovascular Disease Study Could Be Huge

Akcea Therapeutics and Ionis Pharmaceuticals each made handy gains on Wednesday after the firms reported midstage results for their cardiovascular…